PROTON PUMP INHIBITORS MARKET ANALYSIS

Proton Pump Inhibitors Market, By Type (Omeprazole, Pantaprazole, Rabeprazole, Dexlansoprazole, lansoprazole, Others), By Disease Indication (Ulcers, Gastroesophageal Reflux Disease, Others), By Dosage Form (Tablet, Capsules, Injection, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In May 2023, AstraZeneca, a biopharmaceutical company, launched its latest advancement- "ProtonEase XR." This new formulation is an extended-release tablet that is specifically engineered to deliver continuous acid suppression over an extended period, ensuring prolonged efficacy throughout the day.
In September 2022, the U.S. FDA approved omeprazole and sodium bicarbonate for oral suspension (Konvomep, Azurity) to treat active benign gastric ulcers and prevent upper gastrointestinal bleeding in critically ill patients. This new formulation combines the proton pump inhibitor omeprazole with sodium bicarbonate, offering patients a liquid option of this widely prescribed medication to reduce stomach acid and alleviate conditions like heartburn and peptic ulcers.
In April 2022, Daewon Pharmaceutical, a pharmaceutical company, introduced Escorten, one of Korea's initial proton-pump inhibitor medications. It contains esomeprazole magnesium trihydrate in a 10mg formulation.
In January 2022, TWI Pharmaceuticals USA, a technology-based special pharmaceutical company, launched a generic version of Dexilant in the U.S. This dexlansoprazole medication is designed to alleviate heartburn associated with GERD (Gastroesophageal Reflux Disease) and aid in the healing of erosive esophagitis. It is available as delayed-release capsules in 30mg and 60mg strengths.